Insider Trading April 15, 2026 05:47 PM

PennyMac CEO Disposes of 10,000 Shares, Netting $928K Under 10b5-1 Plan

David Spector sold stock amid recent earnings headwinds and a significant year-to-date share-price decline

By Maya Rios PFSI
PennyMac CEO Disposes of 10,000 Shares, Netting $928K Under 10b5-1 Plan
PFSI

David Spector, Chairman and CEO of PennyMac Financial Services (PFSI), sold 10,000 shares on April 14, 2026 under a prearranged Rule 10b5-1 plan, generating roughly $928,279. The transactions leave Spector with both indirect and direct holdings in the company, including restricted stock units. The sale occurs against a backdrop of a 30% year-to-date share decline, a recent fourth-quarter 2025 earnings miss, and mixed analyst reactions.

Key Points

  • CEO David Spector sold 10,000 shares on April 14, 2026 under a Rule 10b5-1 plan, generating approximately $928,279.
  • PennyMac shares have fallen roughly 30% year-to-date, trading at $91.74 and at a P/E of 9.9; InvestingPro analysis indicates the stock is undervalued versus Fair Value.
  • Company developments include a Q4 2025 earnings miss driven by elevated mortgage servicing rights amortization, analyst target adjustments, bylaw changes, and the launch of non-qualified mortgage products via third-party origination.

David Spector, who serves as Chairman and Chief Executive Officer of PennyMac Financial Services, Inc. (NYSE: PFSI), completed a disposition of 10,000 common shares on April 14, 2026, according to a recent filing with the U.S. Securities and Exchange Commission.

The sales were carried out under a pre-established Rule 10b5-1 trading arrangement and produced aggregate proceeds of approximately $928,279. Share prices for the executed transactions ranged from $92.29 to $93.735.

Breaking down the sales, Spector sold 9,583 shares at a weighted average price of $92.80, yielding about $887,378. He also sold a further 417 shares at a weighted average price of $93.47, producing roughly $40,901 in proceeds.

After these transactions, Spector's remaining interests in PennyMac include an indirect holding of 70,604 shares through ST Family Investment Company LLC, plus a direct stake of 529,401 shares. That direct position comprises 37,841 restricted stock units (RSUs) that will convert to an equal number of common shares upon vesting.

The insider sale comes as PennyMac's stock has experienced notable weakness this year. The shares have fallen about 30% year-to-date and were trading at $91.74 at the time of the filing. The company trades at a reported price-to-earnings ratio of 9.9. Analysis from InvestingPro referenced in the filing indicates PennyMac is trading below its Fair Value, and a comprehensive Pro Research Report is available for the company and more than 1,400 other U.S. equities.

PennyMac's recent operating results include a pronounced earnings shortfall in the fourth quarter of 2025. The company attributed pressure to elevated mortgage servicing rights amortization, a factor that drew attention from equity research shops and investors alike.

In the aftermath of the quarterly results, Piper Sandler revised its price target for PennyMac downward from $137 to $122, while maintaining an Overweight rating. By contrast, Keefe, Bruyette & Woods moved to upgrade the stock to Outperform from Market Perform and set a new price target of $115, which they view as implying roughly 38% upside relative to the then-current price, citing valuation and return-on-equity considerations.

Corporate governance adjustments were also disclosed by the company. Amendments to the corporate bylaws clarified voting and agreement references, aligned language with the firm's current corporate name, and updated stockholder agreements.

On the product front, PennyMac expanded its third-party origination division by introducing non-qualified mortgage offerings targeted at self-employed borrowers and entrepreneurs. These products provide a set of income documentation alternatives for applicants whose income profiles do not follow traditional payroll documentation.

Finally, PennyMac's disappointing quarterly results contributed to broader weakness across mortgage originators in the sector, with other issuers such as Rocket Companies experiencing share-price pressure in the same period.


Key points

  • CEO David Spector sold 10,000 PennyMac shares on April 14, 2026 under a Rule 10b5-1 plan, netting about $928,279.
  • PennyMac shares are down roughly 30% year-to-date and were trading at $91.74; the stock trades at a P/E of 9.9 and InvestingPro analysis flags it as trading below Fair Value.
  • Recent company developments include a Q4 2025 earnings miss driven by higher MSR amortization, analyst target adjustments, bylaw revisions, and new non-qualified mortgage products via the third-party origination channel.

Risks and uncertainties

  • Elevated mortgage servicing rights amortization weighed on fourth-quarter 2025 results and is cited as a near-term headwind to earnings - this impacts the mortgage originator and mortgage servicing sectors.
  • Sector-wide volatility following PennyMac's results contributed to a sell-off among mortgage originators, illustrating market sensitivity to operating misses in housing finance names.
  • The company's stock has declined about 30% year-to-date, indicating market risk for equity holders and potential balance-sheet and valuation concerns for investors focused on financials and housing-related equities.

Risks

  • Higher mortgage servicing rights amortization drove a fourth-quarter 2025 earnings shortfall, representing an operating risk for mortgage servicers and originators.
  • Sector sell-off following disappointing results shows market sensitivity and poses downside risk for mortgage originators and related financial stocks.
  • A roughly 30% year-to-date stock decline highlights valuation and market-risk concerns for equity investors in the housing finance and mortgage sectors.

More from Insider Trading

Photronics Director Sells $225,000 in Stock After Exercising Options; Company Posts Quarterly Beat and Advances Mask Capability Apr 15, 2026 Genprex Director Disposes of Small Holding as Company Advances Gene Therapy IP and Data Presentations Apr 15, 2026 Arista CEO Jayshree Ullal Sells $16.9M in ANET Stock Under 10b5-1 Plan Apr 15, 2026 Oruka Therapeutics CMO Disposes $462,829 in Stock as Analysts Lift Targets on ORKA-001 Progress Apr 15, 2026 GameStop General Counsel Disposes of $90.7K in GME Shares Under 10b5-1 Plan Apr 15, 2026